Biodesix and Vanderbilt are developing an AI-driven lung cancer risk test combining blood-based and imaging biomarkers.

Diadem receives a US patent expanding protection for its AlzoSure Predict blood assay, which detects U-p53AZ, a biomarker ...

A Penn State-led team developed a rapid syphilis test that detects low antibody titers in one step, with up to 46% stronger ...

The companies will collaborate with AstraZeneca to advance local lab testing for a prostate cancer genomic instability ...

Beckman Coulter Diagnostics appoints Catherine Jennings, formerly of Boston Scientific as president to lead global operations ...

Nabsys launches RepX, a pipeline on its Navigator platform that analyzes up to 23 disease loci in one run using Electronic ...

New studies presented at ACG 2026 indicate TissueCypher offers objective risk assessment for Barrett’s esophagus progression ...

A peer-reviewed study validates Gnosis' EdenDx cervical sample test, showing 96.8% specificity for endometrial cancer ...

Delve Bio launched Delve Detect Plasma, a blood-based mNGS assay that detects over 68,000 pathogens with next-day results, ...

Labcorp to acquire select BioReference Health assets from OPKO Health for $722 million, including labs, service centers, and ...

Biodesix is presenting data showing Nodify Lung assay’s integration with PET imaging and its impact on lung nodule diagnostic ...

Modeling presented at ACG 2026 shows Guardant Health’s blood-based colorectal cancer screening averts more deaths and ...